After interest surged in the pandemic, companies developing far UV-C decontamination technology face a long road to market
Examples of high-priority "prototype" pathogens (left to right): hantavirus, yellow fever virus, Nipah virus, picornavirus, and Chikungunya. Photo credits: NIAID / Flickr
The development of COVID vaccines took the urgency out of this work, but far UV-C is still seen as a promising technology for pandemic readiness and preventing other infections, such as influenza, tuberculosis and hospital-acquired infections.
The technology itself is mature, but the market is not. Companies hoping to commercialise far UV-C systems face a range of barriers, from hesitancy in the healthcare sector to manufacturing costs that make mass deployment unattractive.
“Healthcare should be the…
Discover the latest in research funding every Tuesday with Funding Newswire. Dive into detailed articles with our monthly or yearly subscriptions or start with a free trial
NOTE: if you're a part of one of our Network member organisations, you get free access by signing up with your institutional email. Verify your eligibility here.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
